OBJECTIVES: To measure the burden of disease and describe the epidemiology of cryptococcosis in Gauteng Province, South Africa. DESIGN AND METHODS: The study was an active, prospective, laboratory-based, population-based surveillance. An incident case of cryptococcosis was defined as the first isolation by culture of any Cryptococcus species from any clinical specimen, a positive India ink cryptococcal latex agglutination test or a positive histopathology specimen from a Gauteng resident. Cases were identified prospectively at all laboratories in Gauteng. Case report forms were completed using medical record review and patient interview where possible. RESULTS: Between 1 March 2002 and 29 February 2004, 2753 incident cases were identified. The overall incidence rate was 15.6/100 000. Among HIV-infected persons, the rate was 95/100 000, and among persons living with AIDS 14/1000. Males and children under 15 years accounted for 49 and 0.9% of cases, respectively. The median age was 34 years (range, 1 month-74 years). Almost all cases (97%) presented with meningitis. Antifungal therapy was given to 2460 (89%) cases of which 72% received fluconazole only. In-hospital mortality was 27% (749 cases). Recurrences occurred in 263 (9.5%) incident cases. Factors associated with death included altered mental status, coma or wasting; factors associated with survival included employment in the mining industry, visual changes or headache on presentation. CONCLUSIONS: This study demonstrates the high disease burden due to cryptococcosis in an antiretroviral-naive South African population and emphasizes the need to improve early recognition, diagnosis and treatment of the condition.
OBJECTIVES: To measure the burden of disease and describe the epidemiology of cryptococcosis in Gauteng Province, South Africa. DESIGN AND METHODS: The study was an active, prospective, laboratory-based, population-based surveillance. An incident case of cryptococcosis was defined as the first isolation by culture of any Cryptococcus species from any clinical specimen, a positive India ink cryptococcal latex agglutination test or a positive histopathology specimen from a Gauteng resident. Cases were identified prospectively at all laboratories in Gauteng. Case report forms were completed using medical record review and patient interview where possible. RESULTS: Between 1 March 2002 and 29 February 2004, 2753 incident cases were identified. The overall incidence rate was 15.6/100 000. Among HIV-infectedpersons, the rate was 95/100 000, and among persons living with AIDS 14/1000. Males and children under 15 years accounted for 49 and 0.9% of cases, respectively. The median age was 34 years (range, 1 month-74 years). Almost all cases (97%) presented with meningitis. Antifungal therapy was given to 2460 (89%) cases of which 72% received fluconazole only. In-hospital mortality was 27% (749 cases). Recurrences occurred in 263 (9.5%) incident cases. Factors associated with death included altered mental status, coma or wasting; factors associated with survival included employment in the mining industry, visual changes or headache on presentation. CONCLUSIONS: This study demonstrates the high disease burden due to cryptococcosis in an antiretroviral-naive South African population and emphasizes the need to improve early recognition, diagnosis and treatment of the condition.
Authors: Nelesh P Govender; Jaymati Patel; Marelize van Wyk; Tom M Chiller; Shawn R Lockhart Journal: Antimicrob Agents Chemother Date: 2011-03-28 Impact factor: 5.191
Authors: Mark W Tenforde; Margaret Mokomane; Tshepo Leeme; Raju K K Patel; Nametso Lekwape; Chandapiwa Ramodimoosi; Bonno Dube; Elizabeth A Williams; Kelebeletse O Mokobela; Ephraim Tawanana; Tlhagiso Pilatwe; William J Hurt; Hannah Mitchell; Doreen L Banda; Hunter Stone; Mooketsi Molefi; Kabelo Mokgacha; Heston Phillips; Paul C Mullan; Andrew P Steenhoff; Yohana Mashalla; Madisa Mine; Joseph N Jarvis Journal: Clin Infect Dis Date: 2017-09-01 Impact factor: 9.079
Authors: Rosalind Parkes-Ratanshi; Katie Wakeham; Jonathan Levin; Deodata Namusoke; James Whitworth; Alex Coutinho; Nathan Kenya Mugisha; Heiner Grosskurth; Anatoli Kamali; David G Lalloo Journal: Lancet Infect Dis Date: 2011-10-06 Impact factor: 25.071
Authors: R Mdodo; K Brown; E Omonge; W Jaoko; J Baddley; P Pappas; M Colette Kempf; I Aban; S Odera; A Suleh; P E Jolly Journal: East Afr Med J Date: 2010-12
Authors: Emily W Bratton; Nada El Husseini; Cody A Chastain; Michael S Lee; Charles Poole; Til Stürmer; David J Weber; Jonathan J Juliano; John R Perfect Journal: Antimicrob Agents Chemother Date: 2013-03-11 Impact factor: 5.191